Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Authors

Yang Wang, Jane McKenzie, Shahneen Sandhu

Published in

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Volume 67. Issue Suppl 2. Pages 20S-29S. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

Prostate-specific membrane antigen is a transmembrane glycoprotein that is highly specific and overexpressed in prostate cancer cells, making it an effective target for theranostics. Despite significant progress in recent years with prostate-specific membrane antigen-targeting radiopharmaceutical therapies that show promising anticancer activity and safety profiles, resistance is inevitable and underpins the need for combinatorial approaches. In this article, we discuss the progress made toward radiopharmaceutical therapy combination approaches, including those involving androgen receptor pathway inhibitors, poly(adenosine diphosphate-ribose) polymerase inhibitors, immunotherapy, and chemotherapy, that are under active investigation.

PMID:
42728101
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.